AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
September 21, 2022 08:45 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 21, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 07:25 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
September 06, 2022 07:30 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
August 30, 2022 07:30 ET
|
AIM ImmunoTech Inc.
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA,...
AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer
August 18, 2022 09:05 ET
|
AIM ImmunoTech Inc.
Company receives IRB approval of study protocol Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with locally...
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 15, 2022 08:05 ET
|
AIM ImmunoTech Inc.
– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term...
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
July 28, 2022 09:10 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., July 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
AIM ImmunoTech报告了评估安普利近(Ampligen)作为晚期胰腺癌维持疗法相关单中心指定患者研究项目的更多患者数据,与之前发布数据相比显示更多无疾病进展和整体存活情况
July 21, 2022 14:59 ET
|
AIM ImmunoTech Inc.
安普利近®(rintatolimod)显示出作为转移性和局部晚期胰腺癌(LACC)患者系统性化疗后潜在维持疗法的具有前景的活性 新的患者数据为推进开发安普利近以用于治疗晚期胰腺癌提供了更多依据 伊拉斯姆斯医学中心C.H.J. van Eijck教授(医学博士、哲学博士)最近在荷兰伊拉默洛第五届多学科胃肠肿瘤学大会上介绍了新数据 佛罗里达州奥卡拉, July 22, 2022 (GLOBE...
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
July 20, 2022 08:05 ET
|
AIM ImmunoTech Inc.
Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC) ...
AIM ImmunoTech宣布最近从Jorgl活动团体收到的董事提名无效
July 18, 2022 12:55 ET
|
AIM ImmunoTech Inc.
向联邦法院提起诉讼,以迫使活动团体透露真实意图(包括对公司的潜在敌意收购)并防止该团体继续违反联邦证券法以及美国证券交易委员会(SEC)和佛罗里达州禁令 诉状列举了某些活动团体成员的严重违法行为和违反信托责任的历史 AIM董事会因该公司存在虚假陈述和违反公司章程的遗漏而一致否决提名通知书 AIM致力于遵循所有股东的最佳利益行事,以防止活动团体在不支付溢价的情况下获得公司董事会控制权 ...